Lung Cancer News and Research

Latest Lung Cancer News and Research

Riverain Medical's bone suppression technology effective for lung nodule detection

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Heparan sulfate may have a key role in tumor-spurred lymphatic vessel growth

Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.

27 Apr 2011

Scripps Research receives $1.9 million NIH grant for prostate cancer study

The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

27 Apr 2011

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

In a new study published online in the journal Cancer, it was said that when faced with life-threatening cancer, minority patients like blacks may be more likely to drain their bank accounts to extend life than whites.

26 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Simple, obvious and obscure ways to keep minds sharp and brains healthy

From a glance at the magazine stands, Americans appear obsessed with losing weight, cutting their cardiac risks and seeking to improve their odds against cancer. But where's the focus on brain health?

25 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

LCA-GA calls on entire Georgia delegation to support Lung Cancer Mortality Reduction Act

Today, Lung Cancer Alliance-Georgia (LCA-GA) thanked Senator Johnny Isakson (R-GA) for being an original sponsor of the Lung Cancer Mortality Reduction Act (S. 752), authorizing legislation that establishes a multi-agency, comprehensive research program addressing all aspects of lung cancer, and called on the entire delegation of Georgia to show their support for the lung cancer community.

22 Apr 2011

Breath test shows promise for detection of head-and-neck cancers

Scientists reveal that an 'electronic nose' can distinguish between molecules found in the breath of head-and-neck cancer patients and those of healthy people, according to the results of a small, initial study published in the British Journal of Cancer, today.

21 Apr 2011

Aduro raises $19.25 million through Series B equity financing

Aduro BioTech, a clinical-stage immunotherapy company, announced today that it has completed its Series B equity financing from a combination of current investors and Morningside Ventures, bringing the total capital secured in this round to $19.25 million. In addition, Ms. Stephanie O'Brien, who represents Morningside, has joined Aduro's Board of Directors.

20 Apr 2011

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

20 Apr 2011

Parents open to genetic tests for children

Genetic testing techniques have not been perfected yet but parents are willing to take the risk to know if their children are at risk for diseases in adulthood. Some parents would like the ability to predict the future, in terms of their child's risk for certain chronic health conditions. This comes in a new study published online in the journal Pediatrics. Experts, however, say the tests are of little value at this time.

19 Apr 2011

Radiology publishes Riverain Medical's SoftView chest X-ray study data in lung cancer

Riverain Medical, an industry leader and innovator in computer-aided detection and advanced visualization technologies, today announced the publication of a peer-reviewed study in Radiology demonstrating that radiologists using Riverain Medical's SoftView bone suppression application with chest X-rays significantly increased their detection of lung nodules proven to be primary lung cancer.

19 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.

19 Apr 2011

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.

18 Apr 2011

Parents may chose predictive genetic tests for their children

Parents offered genetic testing to predict their risks of common, adult-onset health conditions say they would also test their children. That is the finding of a new study published in the May issue of Pediatrics.

18 Apr 2011